As dyslipidemias remain one of the main risk factors for developing cardiovascular disease,
the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of …

Although statin therapy has proven to be the cornerstone for prevention and treatment of
cardiovascular disease (CVD), there are many patients for whom long-term therapy remains …

Background and aims One of the objectives of the ESC-EORP EUROASPIRE V survey is to
determine how well European guidelines on the management of dyslipidaemias are …

Background: Although guidelines recommend in-hospital initiation of high-intensity statin
therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol …

Background and aims Central and Eastern Europe (CEE) is a largely understudied region,
despite having the highest cardiovascular disease mortality in Europe. This analysis aimed …

Background Little is known about the achievement of low density lipoprotein cholesterol
(LDL-C) targets in patients at cardiovascular risk receiving stable lipid-lowering therapy …

Background and aims Low-density lipoprotein cholesterol (LDL-C) is a major contributor to
cardiovascular disease. In the Dyslipidemia International Study II (DYSIS II), we determined …

OBJECTIVE To evaluate the efficacy and safety of inclisiran by diabetes status. RESEARCH
DESIGN AND METHODS ORION-1 (ClinicalTrials. gov, NCT02597127) randomized 501 …

Following an acute coronary syndrome (ACS), heightened predisposition to
atherothrombotic events may persist for years. Advances in understanding the pathobiology …

Atherosclerotic cardiovascular disease (ASCVD) underlies the thrombotic events intimately
associated with myocardial infarction, a significant proportion of ischaemic strokes, as well …